Hennigsdorf/Berlin (Germany), June 23, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. med. Steffen Stürzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022. Dr. Stürzebecher is
by Ian Schofield Executive Summary RedHill’s opaganib has shown “potent inhibition” of the Omicron variant in early studies, while the EMA has found nolinks between the mRNA vaccines and autoimmune hepatitis. Read the full
Adrecizumab selected to receive funding from two COVID-19 drug development programs of the German Federal Ministry of Education and Research (BMBF) By restoring vascular integrity, Adrecizumab addresses the endothelial barrier dysfunction as a consequence of
Hennigsdorf/Berlin (Germany), 15 March, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. Richard Jones as Chief Executive Officer of Adrenomed, effective today. Dr. Jones brings over 25 years of
In March, Adrenomed will be attending the 41st International Symposium on Intensive Care & Emergency Medicine, Brussels, Belgium. Conference dates: 22 – 25 March 2022 Additionally, Adrenomed will participate in BIO-Europe Spring (digital) Conference dates: